Circulating 25-hydroxyvitamin D and postmenopausal breast cancer survival: Influence of tumor characteristics and lifestyle factors?

International Journal of Cancer

Volumn 134, Issue 12, 2014, Pages 2972-2983

  Vrieling, Alina ^a,b   Seibold, Petra ^a   Johnson, Theron S ^a   Heinz, Judith ^c   Obi, Nadia ^c   Kaaks, Rudolf ^a   Flesch Janys, Dieter ^c   Chang Claude, Jenny ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

25(OH)D; breast neoplasms; mortality; recurrence; vitamin D

Indexed keywords

25 HYDROXYVITAMIN D;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; FOLLOW UP; GERMANY; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

25(OH)D; BREAST NEOPLASMS; MORTALITY; RECURRENCE; VITAMIN D;

AGED; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GERMANY; HUMANS; LIFE STYLE; MIDDLE AGED; NEOPLASM STAGING; POSTMENOPAUSE; PROSPECTIVE STUDIES; RISK; RISK FACTORS; SURVIVAL; VITAMIN D;

EID: 84897977916     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28628     Document Type: Article

References (36)

1. Holick MF,. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol 2009; 19: 73-8.
2. Yin L, Grandi N, Raum E, et al. Meta-analysis: serum vitamin D and breast cancer risk. Eur J Cancer 2010; 46: 2196-205.
3. Goodwin PJ, Ennis M, Pritchard KI, et al. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 2009; 27: 3757-63.
4. Vrieling A, Hein R, Abbas S, et al. Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study. Breast Cancer Res 2011; 13: R74.
5. Kim HJ, Lee YM, Ko BS, et al. Vitamin D deficiency is correlated with poor outcomes in patients with luminal-type breast cancer. Ann Surg Oncol 2011; 18: 1830-6.
6. Hatse S, Lambrechts D, Verstuyf A, et al. Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency. Carcinogenesis 2012; 33: 1319-26.
7. Tretli S, Schwartz GG, Torjesen PA, et al. Serum levels of 25-hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma: a population-based study. Cancer Causes Control 2012; 23: 363-70.
8. Jacobs ET, Thomson CA, Flatt SW, et al. Vitamin D and breast cancer recurrence in the Women's Healthy Eating and Living (WHEL) Study. Am J Clin Nutr 2011; 93: 108-17.
9. Pritchard KI, Shepherd LE, Chapman JA, et al. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. J Clin Oncol 2011; 29: 3869-76.
10. Villaseñor A, Ballard-Barbash R, Ambs A, et al. Associations of serum 25-hydroxyvitamin D with overall and breast cancer-specific mortality in a multiethnic cohort of breast cancer survivors. Cancer Causes Control 2013; 24: 759-67.
11. Palmieri C, MacGregor T, Girgis S, et al. Serum 25-hydroxyvitamin D levels in early and advanced breast cancer. J Clin Pathol 2006; 59: 1334-6.
12. Neuhouser ML, Sorensen B, Hollis BW, et al. Vitamin D insufficiency in a multiethnic cohort of breast cancer survivors. Am J Clin Nutr 2008; 88: 133-9.
13. Lagunova Z, Porojnicu AC, Lindberg F, et al. The dependency of vitamin D status on body mass index, gender, age and season. Anticancer Res 2009; 29: 3713-20.
14. McCullough ML, Weinstein SJ, Freedman DM, et al. Correlates of circulating 25-hydroxyvitamin D: cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol 2010; 172: 21-35.
15. Bertrand KA, Giovannucci E, Liu Y, et al. Determinants of plasma 25-hydroxyvitamin D and development of prediction models in three US cohorts. Br J Nutr 2012: 1-8.
16. Perna L, Haug U, Schottker B, et al. Public health implications of standardized 25-hydroxyvitamin D levels: a decrease in the prevalence of vitamin D deficiency among older women in Germany. Prev Med 2012; 55: 228-32.
17. Kluczynski MA, Lamonte MJ, Mares JA, et al. Duration of physical activity and serum 25-hydroxyvitamin D status of postmenopausal women. Ann Epidemiol 2011; 21: 440-9.
18. Sowers MR, Wallace RB, Hollis BW, et al. Parameters related to 25-OH-D levels in a population-based study of women. Am J Clin Nutr 1986; 43: 621-8.
19. van Hoof HJ, van der Mooren MJ, Swinkels LM, et al. Hormone replacement therapy increases serum 1,25-dihydroxyvitamin D: a 2-year prospective study. Calcif Tissue Int 1994; 55: 417-9.
20. Brock K, Huang WY, Fraser DR, et al. Low vitamin D status is associated with physical inactivity, obesity and low vitamin D intake in a large US sample of healthy middle-aged men and women. J Steroid Biochem Mol Biol 2010; 121: 462-6.
21. Brot C, Jorgensen NR, Sorensen OH,. The influence of smoking on vitamin D status and calcium metabolism. Eur J Clin Nutr 1999; 53: 920-6.
22. Flesch-Janys D, Slanger T, Mutschelknauss E, et al. Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer 2008; 123: 933-41.
23. Abbas S, Linseisen J, Slanger T, et al. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer-results of a large case-control study. Carcinogenesis 2008; 29: 93-9.
24. Hudis CA, Barlow WE, Costantino JP, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007; 25: 2127-32.
25. Therneau TM, Grambsch PM,. Modeling survival data. Extending the Cox model. Statistics for biology and health. New York: Springer, 2000.
26. Royston P, Ambler G, Sauerbrei W,. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 1999; 28: 964-74.
27. Grambsch PM, Therneau TM,. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994; 81: 515-26.
28. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
29. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2008.
30. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, et al. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 2006; 11: 193-206.
31. Sterne JA, Egger M,. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001; 54: 1046-55.
32. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
33. Santini D, Galluzzo S, Vincenzi B, et al. Longitudinal evaluation of vitamin D plasma levels during anthracycline- and docetaxel-based adjuvant chemotherapy in early-stage breast cancer patients. Ann Oncol 2010; 21: 185-6.
34. Kailajarvi ME, Salminen EK, Paija OM, et al. Serum bone markers in breast cancer patients during 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy. Anticancer Res 2004; 24: 1271-4.
35. Crew KD, Shane E, Cremers S, et al. High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol 2009; 27: 2151-6.
36. Ng K, Meyerhardt JA, Wu K, et al. Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. J Clin Oncol 2008; 26: 2984-91.